BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 32942796)

  • 1. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.
    Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L
    Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
    Kaye RJ
    Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
    Qin H; Zhao A
    Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
    Al-Khawaga S; Abdelalim EM
    Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
    Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P
    Front Immunol; 2020; 11():1091. PubMed ID: 32574263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
    Rogers CJ; Harman RJ; Bunnell BA; Schreiber MA; Xiang C; Wang FS; Santidrian AF; Minev BR
    J Transl Med; 2020 May; 18(1):203. PubMed ID: 32423449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential.
    Khoury M; Rocco PRM; Phinney DG; Krampera M; Martin I; Viswanathan S; Nolta JA; LeBlanc K; Galipeau J; Weiss DJ
    Cytotherapy; 2020 Nov; 22(11):602-605. PubMed ID: 32933835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
    Khoury M; Cuenca J; Cruz FF; Figueroa FE; Rocco PRM; Weiss DJ
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32265310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.
    Jayaramayya K; Mahalaxmi I; Subramaniam MD; Raj N; Dayem AA; Lim KM; Kim SJ; An JY; Lee Y; Choi Y; Raj A; Cho SG; Vellingiri B
    BMB Rep; 2020 Aug; 53(8):400-412. PubMed ID: 32731913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation and Regeneration Properties of Dental Pulp Stem Cells: A Potential Therapy to Treat Coronavirus Disease 2019.
    Zayed M; Iohara K
    Cell Transplant; 2020; 29():963689720952089. PubMed ID: 32830527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].
    Wang J; Zou W; Liu J
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1970-1978. PubMed ID: 33169563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.
    Shu L; Niu C; Li R; Huang T; Wang Y; Huang M; Ji N; Zheng Y; Chen X; Shi L; Wu M; Deng K; Wei J; Wang X; Cao Y; Yan J; Feng G
    Stem Cell Res Ther; 2020 Aug; 11(1):361. PubMed ID: 32811531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
    Lu W; Yan L; Tang X; Wang X; Du J; Zou Z; Li L; Ye J; Zhou L
    J Transl Med; 2024 Jun; 22(1):550. PubMed ID: 38851730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
    Sengupta V; Sengupta S; Lazo A; Woods P; Nolan A; Bremer N
    Stem Cells Dev; 2020 Jun; 29(12):747-754. PubMed ID: 32380908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?
    Muraca M; Pessina A; Pozzobon M; Dominici M; Galderisi U; Lazzari L; Parolini O; Lucarelli E; Perilongo G; Baraldi E
    J Control Release; 2020 Sep; 325():135-140. PubMed ID: 32622963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.
    Xiao K; Hou F; Huang X; Li B; Qian ZR; Xie L
    Stem Cell Res Ther; 2020 Jul; 11(1):305. PubMed ID: 32698898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stem cell research progress for the treatment of COVID-19.
    Yao D; Ye H; Huo Z; Wu L; Wei S
    J Int Med Res; 2020 Sep; 48(9):300060520955063. PubMed ID: 32972277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].
    Shi X; Yu L; Ding C
    Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):1979-1991. PubMed ID: 33169564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.